Published in J Exp Med on January 01, 1982
Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun (1992) 3.21
The structure and function of human IgA. Biochem J (1990) 2.65
Defense mechanisms involving Fc-dependent functions of immunoglobulin A and their subversion by bacterial immunoglobulin A proteases. Microbiol Rev (1988) 2.50
Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci U S A (1992) 2.24
Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol (1995) 1.88
Oral microbial ecology and the role of salivary immunoglobulin A. Microbiol Mol Biol Rev (1998) 1.81
Experimental IgA nephropathy induced by oral immunization. J Exp Med (1983) 1.45
Clearance of circulating IgA immune complexes is mediated by a specific receptor on Kupffer cells in mice. J Exp Med (1984) 1.31
Acute lung injury in rat caused by immunoglobulin A immune complexes. J Clin Invest (1984) 1.29
Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology (1992) 1.19
Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation. Proc Natl Acad Sci U S A (2006) 1.14
Mesangial cell autoantigens in immunoglobulin A nephropathy and Henoch-Schönlein purpura. J Clin Invest (1991) 0.97
In vivo activation of complement by IgA in a rat model. Clin Exp Immunol (1992) 0.88
In vitro activation of rat neutrophils and alveolar macrophages with IgA and IgG immune complexes. Implications for immune complex-induced lung injury. Am J Pathol (1987) 0.86
Rheumatoid factors in cystic fibrosis: associations with disease manifestations and recurrent bacterial infections. Clin Exp Immunol (1989) 0.84
IgA and IgG immune complexes increase human macrophage C3 biosynthesis. Immunology (1995) 0.82
Experimental cholestasis promotes the deposition of glomerular IgA immune complexes. Am J Pathol (1983) 0.79
Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. Haematologica (2012) 0.78
Activation of human monocytes via their sIgA receptors. Immunology (1991) 0.78
Potential of immunoglobulin A to prevent allergic asthma. Clin Dev Immunol (2013) 0.78
Non FcR-binding murine antihuman CD3 monoclonal antibody is capable of productive TCR signalling and induces proliferation in the presence of costimulation. Clin Exp Immunol (2001) 0.77
C3, C4, factor B and HLA-DR alpha mRNA expression in renal biopsy specimens from patients with IgA nephropathy. Immunology (1995) 0.76
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry (1978) 22.56
QUANTITATIVE STUDIES ON THE PRECIPITIN REACTION : ANTIBODY PRODUCTION IN RABBITS INJECTED WITH AN AZO PROTEIN. J Exp Med (1933) 13.12
Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement. J Immunol (1967) 8.06
Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry (1976) 7.80
The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis. J Exp Med (1966) 6.50
Enharncement of the hemolytic activity of the second component of human complement by oxidation. J Exp Med (1967) 5.36
Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci U S A (1978) 4.94
Protein iodination with solid state lactoperoxidase. Biochemistry (1974) 4.52
Crossed immunoelectrophoresis. Scand J Immunol Suppl (1973) 4.51
Interaction between the third complement protein and cell surface macromolecules. Proc Natl Acad Sci U S A (1977) 4.48
Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci U S A (1978) 4.43
Affinity labeling of a phosphorylcholine binding mouse myeloma protein. Biochemistry (1972) 4.26
The IgA system. I. Studies of the transport and immunochemistry of IgA in the saliva. J Exp Med (1966) 3.97
Electrophoretic heterogeneity of polypeptide chains of specific antibodies. Science (1966) 3.88
The reaction mechanism of human C5 in immune hemolysis. J Exp Med (1970) 3.83
Serological properties of gamma-A antibodies to Escherichia coli present in human colostrum. Immunology (1966) 3.11
Hemolytic activity of lipoprotein-depleted serum and the effect of certain anions on complement. J Immunol (1966) 2.98
Mechanism of binding of soluble immune complexes to lymphocytes. Cell Immunol (1973) 2.93
Action of the C3b-inactivator on the cell-bound C3b. J Immunol (1979) 2.81
The release of granule enzymes from human neutrophils stimulated by aggregated immunoglobulins of different classes and subclasses. J Immunol (1972) 2.80
The isolation and structure of C4, the fourth component of human complement. Biochem J (1977) 2.61
A new one-step method for the functional assay of the fourth component (C4) of human and guinea pig complement. J Immunol (1974) 2.60
The uniqueness of human milk. Host resistance to infection. Am J Clin Nutr (1971) 2.48
Cellular aspects of immunoglobulin A. Adv Immunol (1976) 2.44
Coupling of large haptens to proteins and cell surfaces: preparation of stable, optimally sensitized erythrocytes for hapten-specific, hemolytic plaque assays. Immunochemistry (1973) 2.21
Structural and functional differences between the H-2 controlled Ss and Slp proteins. J Exp Med (1978) 1.85
Phagocytosis in subacute bacterial endocarditis. Localization of the primary opsonic site to Fc fragment. J Exp Med (1968) 1.80
Mechanism of solubilization of immune aggregates by complement. Implications for immunopathology. Transplant Rev (1976) 1.80
Covalent binding and hemolytic activity of complement proteins. Proc Natl Acad Sci U S A (1980) 1.77
Heterogeneity of the BALB/c antiphosphorylcholine antibody response at the precursor cell level. J Exp Med (1975) 1.75
Immunochemical properties of human gamma-A isohemagglutinin. I. Comparisons with gamma-G and gamma-M-globulin antibodies. J Immunol (1965) 1.72
The pathogenesis of dermatitis herpetiformis. J Invest Dermatol (1978) 1.70
The serine protease nature of the C3 and C5 convertases of the classical and alternative complement pathways. Scand J Immunol (1976) 1.67
Lack of opsonization potential of 11S human secretory A. Proc Soc Exp Biol Med (1973) 1.56
Evidence for the presence of components of the alternative (properdin) pathway of complement activation in respiratory secretions. J Immunol (1976) 1.29
The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway. J Immunol (1981) 1.26
The complement system in necrotizing angiitis of the skin. Analysis of complement component activities in serum of patients with concomitant collagen-vascular diseases. J Invest Dermatol (1974) 1.24
Surface and intracellular markers of mouse mesenteric and peripheral lymph node and Peyer's patch cells. J Immunol (1974) 1.23
A new function of the activated third component of complement: binding to C5, an essential step for C5 activation. Immunology (1978) 1.20
The interactions of human complement with interfacially aggregated preparations of human secretory IgA. Immunochemistry (1974) 1.19
Ontogenetic development of the complement system. Immunology (1969) 1.19
The relative antibacterial efficiency of IgM, IgG and IgA from pig colostrum. Aust J Exp Biol Med Sci (1971) 1.17
Complement fixing abilities of IgA myeloma proteins and their fragments: the activation of complement through the classical pathway. Immunochemistry (1976) 1.11
Developmental aspects of complement components in the newborn. The presence of complement components and C3 proactivator (properdin factor B) in human colostrum. Clin Exp Immunol (1974) 1.01
Solubilization of IgA immune precipitates by complement. J Immunol (1976) 0.96
Lack of C3 activation through classical or alternate pathways by human secretory IgA anti blood group A antibody. Adv Exp Med Biol (1974) 0.95
Activation of the classical complement pathway by Fc fragment of human IgA. J Immunol (1977) 0.94
Secretory IgA and direct killing of Shigella by serum components. Adv Exp Med Biol (1974) 0.84
Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. Immunochemistry (1966) 15.12
Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3. Exp Cell Res (1968) 6.20
Improved complementation in the cytotoxic test. Transplantation (1970) 3.93
Organ and isotype distribution of plasma cells producing specific antibody after oral immunization: evidence for a generalized secretory immune system. J Immunol (1979) 3.37
Cell surface immunoglobulin. XI. The appearance of an IgD-like molecule on murine lymphoid cells during ontogeny. J Exp Med (1975) 3.26
The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis. J Immunol (1968) 3.24
The polymeric immunoglobulin receptor translocates pneumococci across human nasopharyngeal epithelial cells. Cell (2000) 3.19
The unactivated form of the first component of human complement, C1. Biochem J (1976) 3.12
The complement system of man. I. N Engl J Med (1972) 3.09
Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J Exp Med (1978) 2.98
Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc Natl Acad Sci U S A (1979) 2.73
The isolation and structure of C4, the fourth component of human complement. Biochem J (1977) 2.61
Human C4-binding protein. I. Isolation and characterization. J Exp Med (1978) 2.60
Cellular aspects of immunoglobulin A. Adv Immunol (1976) 2.44
Charge of circulating immune complexes as a factor in glomerular basement membrane localization in mice. J Clin Invest (1981) 2.24
Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci U S A (1992) 2.24
Langerhans cells: role in contact hypersensitivity and relationship to lymphoid dendritic cells and to macrophages. Immunol Rev (1980) 2.10
Interaction of plasma kallikrein with the C1 inhibitor. J Immunol (1970) 2.07
The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA. Proc Natl Acad Sci U S A (1991) 2.02
Polypeptide chain structure of rabbit immunoglobulins. I. gamma-G-immunoglobulin. Biochemistry (1966) 2.00
Localization of free and bound secretory component in human intestinal epithelial cells. A model for the assembly of secretory IgA. J Exp Med (1974) 1.91
Combined oral/nasal immunization protects mice from Sendai virus infection. J Immunol (1987) 1.90
Structural and functional differences between the H-2 controlled Ss and Slp proteins. J Exp Med (1978) 1.85
A three-tiered view of the role of IgA in mucosal defense. Immunol Today (1993) 1.84
Characteristics of mesenteric lymph node cells homing to gut-associated lymphoid tissue in syngeneic mice. J Immunol (1975) 1.84
Polypeptide chain structure of rabbit immunoglobulins. II. gamma-M-immunoglobulin. Biochemistry (1966) 1.84
Enhancement of random migration and chemotactic response of human leukocytes by ascorbic acid. J Clin Invest (1974) 1.81
Fluid phase destruction of C2hu by C1hu. II. Unmasking by C4ihu of C1hu specificity for C2hu. J Exp Med (1969) 1.78
The structure and enzymic activities of the C1r and C1s subcomponents of C1, the first component of human serum complement. Biochem J (1977) 1.78
Origin of IgA-secreting plasma cells in the mammary gland. J Exp Med (1977) 1.71
Cell surface immunoglobulin. X. Identification of an IgD-like molecule on the surface of murine splenocytes. J Exp Med (1974) 1.70
Mesenteric lymph node B lymphoblasts which home to the small intestine are precommitted to IgA synthesis. J Exp Med (1977) 1.63
Modulation of TL (thymus-leukemia) antigens by Fab-fragments of TL antibody. J Immunol (1968) 1.62
Synthesis of immunoglobulin heavy and light chains by the free ribosomes of a mouse plasma cell tumor. Proc Natl Acad Sci U S A (1970) 1.62
Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus. J Immunol (1988) 1.60
Modulation of function of the activated first component of complement by a fragment derived from serum. I. Effect on early components of complement. J Exp Med (1971) 1.54
Staining of Langerhans cells with monoclonal antibodies to macrophages and lymphoid cells. Proc Natl Acad Sci U S A (1983) 1.50
The complement system of man (second of four parts). N Engl J Med (1972) 1.47
Immunoglobulin-bearing and complement-receptor lymphocytes constitute the same population in human peripheral blood. J Clin Invest (1976) 1.46
Inhibition by epsilon-aminocaproic acid of the activation of the first component of the complement system. J Immunol (1975) 1.46
Unstable inter-H chain disulfide bonding and non-covalently associated J chain in rat dimeric IgA. Mol Immunol (1993) 1.45
A neutrophil immobilizing factor derived from human leukocytes. II. Specificity of action on polymorphonuclear leukocyte mobility. J Immunol (1973) 1.45
Experimental IgA nephropathy induced by oral immunization. J Exp Med (1983) 1.45
Immunoglobulin A monoclonal antibodies protect against Sendai virus. J Virol (1987) 1.44
Presence of two types of L polypeptide chains in guinea pig 7S immunoglobulins. J Exp Med (1966) 1.43
The complement system of man. 3. N Engl J Med (1972) 1.41
IgA nephropathy: pathogenesis of the most common form of glomerulonephritis. Lab Invest (1989) 1.41
Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. J Clin Invest (1986) 1.40
Inhibition of microbial IgA proteases by human secretory IgA and serum. Mol Immunol (1983) 1.38
The complement system of man. 4. N Engl J Med (1972) 1.36
Studies on cell-free synthesis of rat immunoglobulins, II. Synthesis of immunoglobulin and of antibody to the dinitrophenyl hapten. Proc Natl Acad Sci U S A (1967) 1.32
Protein disulphide-isomerase from human placenta and rat liver. Purification and immunological characterization with monoclonal antibodies. Biochem J (1987) 1.31
Hormonal induction of the secretory immune system in the mammary gland. Proc Natl Acad Sci U S A (1978) 1.29
Synthesis of secretory component by colonic neoplasms. Am J Pathol (1976) 1.29
Cell-free synthesis of rat immunoglobulin. 3. Analysis of the cell-free made chains and of their mode of assembly. J Mol Biol (1971) 1.26
The complement system in necrotizing angiitis of the skin. Analysis of complement component activities in serum of patients with concomitant collagen-vascular diseases. J Invest Dermatol (1974) 1.24
Nephritogenicity and differential distribution of glomerular immune complexes related to immunogen charge. Lab Invest (1983) 1.24
Surface and intracellular markers of mouse mesenteric and peripheral lymph node and Peyer's patch cells. J Immunol (1974) 1.23
Phylogeny and function of the complement system. Annu Rev Microbiol (1971) 1.22
Isolation of purified H and L polypeptide chains from guinea-pig gamma-2-immunoglobulin after mild reduction. Immunology (1966) 1.22
Regulation of the immune response: suppressive and enhancing effects of passively administered antibody. J Exp Med (1971) 1.20
Human secretory component. Comparison of the form occurring in exocrine immunoglobulin A to the free form. Biochemistry (1972) 1.18
Activation of complement by pathogenic and nonpathogenic Entamoeba histolytica. J Immunol (1986) 1.18
The interaction of human plasma fibronectin with a subunit of the first component of complement, C1q. J Immunol (1982) 1.18
Plasma cells and epithelial immunoglobulins in the mouse mammary gland during pregnancy and lactation. J Immunol (1977) 1.17
Fluid phase destruction of C2hu by C1hu. I. Its enhancement and inhibition by homologous and heterologous C4. J Exp Med (1969) 1.15
Endocytosis and shedding of the decay accelerating factor on human polymorphonuclear cells. J Immunol (1989) 1.13
Role of complement in porphyrin-induced photosensitivity. J Invest Dermatol (1981) 1.13
IgA nephropathy: overproduction or decreased clearance of immune complexes? Lab Invest (1989) 1.11
Secretory immunoglobulins in colonic neoplasms. Am J Pathol (1976) 1.10
Urticaria and arthralgias as manifestations of necrotizing angiitis (vasculitis). J Invest Dermatol (1974) 1.09
Biologic activities of rabbit immunoglobulin G in relation to domains of the Fc region. J Immunol (1976) 1.09
Selective chemotaxis of subsets of B lymphocytes from gut-associated lymphoid tissue and its implications for the recruitment of mucosal plasma cells. J Immunol (1986) 1.08
Cleavage of C3 by a neutral cysteine proteinase of Entamoeba histolytica. J Immunol (1989) 1.08
Two distinct cellular patterns in cutaneous necrotizing angiitis. J Invest Dermatol (1976) 1.07
Complement receptors on guinea pig epidermal Langerhans cells. J Immunol (1980) 1.06
Effect of glucocorticosteroids on epidermal Langerhans cells. J Exp Med (1982) 1.06
IgA nephropathy: perspectives on pathogenesis and classification. Clin Nephrol (1985) 1.05
A single chain precursor of C4 in human serum. Nature (1978) 1.04
Gut-associated lymphoid tissue as source of an IgA immune response in respiratory tissues after oral immunization and intrabronchial challenge. Cell Immunol (1987) 1.03
Proteolytic enzyme treatment reduces glomerular immune deposits and proteinuria in passive Heymann nephritis. J Exp Med (1986) 1.02
Nondissociating cationic immune complexes can deposit in glomerular basement membrane. J Exp Med (1983) 1.01
Enzymolysis of glomerular immune deposits in vivo with dextranase/protease ameliorates proteinuria, hematuria, and mesangial proliferation in murine experimental IgA nephropathy. J Clin Invest (1990) 1.00
A mucosal IgA-mediated excretory immune system in vivo. J Immunol (2001) 1.00
Evolutionary relationships among proteins encoded by the regulator of complement activation gene cluster. Mol Biol Evol (2000) 0.99
The extracellular neutral cysteine proteinase of Entamoeba histolytica degrades anaphylatoxins C3a and C5a. J Immunol (1995) 0.99
Cell surface immunoglobulin. XIV. Synthesis, surface expression, and secretion of immunoglobulin by Peyer's patch cells in the mouse. J Immunol (1975) 0.99
Mechanism of killing of Giardia lamblia trophozoites by complement. J Clin Invest (1987) 0.98
Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J Clin Invest (1995) 0.98
The role of mesangial complement in the hematuria of experimental IgA nephropathy. Lab Invest (1987) 0.98
Removal of glomerular immune complexes in passive serum sickness nephritis by treatment in vivo with proteolytic enzymes. Lab Invest (1986) 0.98
Transport of serum IgA into murine respiratory secretions and its implications for immunization strategies. J Immunol (1989) 0.97
Migration and regulation of B-cells in the mucosal immune system. Ann N Y Acad Sci (1983) 0.97
Comparative studies of transcytosis and assembly of secretory IgA in Madin-Darby canine kidney cells expressing human polymeric Ig receptor. J Immunol (1995) 0.97
Control mechanisms of the classical and alternate complement sequences. Transplant Proc (1974) 0.97
Regulation and deregulation of the fluid-phase classical pathway C3 convertase. J Immunol (1985) 0.97
Generation of chemotactic activity in serum from patients with erythropoietic protoporphyria and porphyria cutanea tarda. N Engl J Med (1981) 0.97
A phagocytosis-enhancing factor in human plasma. Immunology (1976) 0.96
Fibronectin binding to complement subcomponent C1q. Localization of their respective binding sites. Biochem J (1985) 0.96